Rocket Pharmaceuticals, Inc. (RCKT)
2.655
+0.06
(+2.12%)
USD |
NASDAQ |
Jun 11, 16:00
2.655
0.00 (0.00%)
After-Hours: 17:14
Rocket Pharmaceuticals Enterprise Value : 164.11M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 164.11M |
| June 09, 2026 | 169.56M |
| June 08, 2026 | 175.02M |
| June 05, 2026 | 180.48M |
| June 04, 2026 | 199.03M |
| June 03, 2026 | 199.03M |
| June 02, 2026 | 195.75M |
| June 01, 2026 | 209.94M |
| May 29, 2026 | 215.39M |
| May 28, 2026 | 209.94M |
| May 27, 2026 | 206.87M |
| May 26, 2026 | 207.97M |
| May 22, 2026 | 203.60M |
| May 21, 2026 | 219.98M |
| May 20, 2026 | 204.69M |
| May 19, 2026 | 199.23M |
| May 18, 2026 | 215.61M |
| May 15, 2026 | 235.26M |
| May 14, 2026 | 251.64M |
| May 13, 2026 | 273.48M |
| May 12, 2026 | 277.85M |
| May 11, 2026 | 272.39M |
| May 08, 2026 | 276.76M |
| May 07, 2026 | 281.13M |
| May 06, 2026 | 301.87M |
| Date | Value |
|---|---|
| May 05, 2026 | 266.93M |
| May 04, 2026 | 274.57M |
| May 01, 2026 | 269.11M |
| April 30, 2026 | 260.31M |
| April 29, 2026 | 260.31M |
| April 28, 2026 | 254.85M |
| April 27, 2026 | 261.40M |
| April 24, 2026 | 264.68M |
| April 23, 2026 | 281.96M |
| April 22, 2026 | 295.06M |
| April 21, 2026 | 279.78M |
| April 20, 2026 | 301.60M |
| April 17, 2026 | 307.06M |
| April 16, 2026 | 305.97M |
| April 15, 2026 | 303.78M |
| April 14, 2026 | 277.60M |
| April 13, 2026 | 277.60M |
| April 10, 2026 | 261.23M |
| April 09, 2026 | 273.23M |
| April 08, 2026 | 273.23M |
| April 07, 2026 | 260.14M |
| April 06, 2026 | 257.95M |
| April 02, 2026 | 267.77M |
| April 01, 2026 | 275.41M |
| March 31, 2026 | 271.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Replimune Group, Inc. | 481.69M |
| ProKidney Corp. | 1.303B |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sangamo Therapeutics, Inc. | 53.47M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -47.59M |
| Total Expenses (Quarterly) | 47.59M |
| EPS Diluted (Quarterly) | -0.4244 |
| Earnings Yield | -70.69% |
| Normalized Earnings Yield | -69.85 |